Microneedle transdermal delivery of compound betamethasone in alopecia areata—A randomized controlled trial

IF 12.8 1区医学 Q1 DERMATOLOGY

Journal of the American Academy of Dermatology Pub Date : 2025-02-01 DOI:10.1016/j.jaad.2024.09.059

Rui Qiao MD, Jiaping Zhu MD, Jing Fang MD, Hualing Shi MD, Ziye Zhang MD, Jin Nie MD, Yiping Ge MD, Tong Lin MD, Yiqun Jiang MD

{"title":"Microneedle transdermal delivery of compound betamethasone in alopecia areata—A randomized controlled trial","authors":"Rui Qiao MD, Jiaping Zhu MD, Jing Fang MD, Hualing Shi MD, Ziye Zhang MD, Jin Nie MD, Yiping Ge MD, Tong Lin MD, Yiqun Jiang MD","doi":"10.1016/j.jaad.2024.09.059","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Alopecia areata (AA) places a considerable burden on patients. While intralesional glucocorticoid injection is an important therapy, it can cause severe pain.</div></div><div><h3>Objective</h3><div>To compare the efficacy and pain levels of microneedle transdermal delivery of compound betamethasone versus traditional intralesional injection in mild-to-moderate AA.</div></div><div><h3>Methods</h3><div>We conducted a randomized controlled trial in AA patients with a Severity of Alopecia Tool (SALT) score <50. Both groups received monthly compound betamethasone injections: group A via intralesional injections and group B via transdermal microneedle delivery. The primary outcome was the reduction in SALT score after 3 months.</div></div><div><h3>Results</h3><div>With 80 patients enrolled, baseline SALT scores were similar between group A (9.250 ± 5.300) and group B (10.65 ± 9.445). After 3 months, the mean SALT reduction was 7.000 ± 4.5017 in group A and 8.075 ± 8.014 in group B, with no statistical difference. Remission rates for SALT30/50/75/90 were 92.50/90.00/57.50/42.50% in group A and 95.00/87.50/72.50/40% in group B, with no significant difference. Group B had a significantly lower visual analog scale pain score than group A (4.000 ± 1.174 vs 5.281 ± 2.098, <em>P</em> = .0047).</div></div><div><h3>Limitations</h3><div>The study focused on mild-to-moderate patchy AA, limiting insights into severe cases.</div></div><div><h3>Conclusion</h3><div>Microneedle transdermal delivery of compound betamethasone in mild-to-moderate patchy AA demonstrates efficacy comparable to traditional intralesional injection with reduced pain.</div></div>","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":"92 2","pages":"Pages 269-275"},"PeriodicalIF":12.8000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the American Academy of Dermatology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0190962224029943","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Alopecia areata (AA) places a considerable burden on patients. While intralesional glucocorticoid injection is an important therapy, it can cause severe pain.

Objective

To compare the efficacy and pain levels of microneedle transdermal delivery of compound betamethasone versus traditional intralesional injection in mild-to-moderate AA.

Methods

We conducted a randomized controlled trial in AA patients with a Severity of Alopecia Tool (SALT) score <50. Both groups received monthly compound betamethasone injections: group A via intralesional injections and group B via transdermal microneedle delivery. The primary outcome was the reduction in SALT score after 3 months.

Results

With 80 patients enrolled, baseline SALT scores were similar between group A (9.250 ± 5.300) and group B (10.65 ± 9.445). After 3 months, the mean SALT reduction was 7.000 ± 4.5017 in group A and 8.075 ± 8.014 in group B, with no statistical difference. Remission rates for SALT30/50/75/90 were 92.50/90.00/57.50/42.50% in group A and 95.00/87.50/72.50/40% in group B, with no significant difference. Group B had a significantly lower visual analog scale pain score than group A (4.000 ± 1.174 vs 5.281 ± 2.098, P = .0047).

Limitations

The study focused on mild-to-moderate patchy AA, limiting insights into severe cases.

Conclusion

Microneedle transdermal delivery of compound betamethasone in mild-to-moderate patchy AA demonstrates efficacy comparable to traditional intralesional injection with reduced pain.

查看原文本刊更多论文

微针透皮给药复方倍他米松治疗脱发--随机对照试验

背景：斑秃（AA）给患者造成了相当大的负担。虽然局部注射糖皮质激素是一种重要的治疗方法，但可能会引起剧烈疼痛：比较微针透皮给药复方倍他米松与传统的局部注射对轻度至中度 AA 的疗效和疼痛程度：我们对SALT评分小于50分的AA患者进行了随机对照试验。两组患者均接受每月一次的复方倍他米松注射：A组通过穴内注射，B组通过透皮微针给药。主要结果是三个月后 SALT 分数的降低：结果：80 名患者中，A 组（9.250±5.300）和 B 组（10.65±9.445）的基线 SALT 评分相似。3 个月后，A 组的 SALT 平均减分率为 7.000±4.5017，B 组为 8.075±8.014，无统计学差异。A 组 SALT30/50/75/90 的缓解率为 92.50/90.00/57.50/42.50%，B 组为 95.00/87.50/72.50/40%，无明显差异。B组的视觉模拟量表（VAS）疼痛评分明显低于A组（4.000±1.174 vs. 5.281±2.098，P=0.0047）：局限性：该研究侧重于轻度至中度斑块状 AA，对严重病例的了解有限：微针透皮给药复合倍他米松治疗轻度至中度斑块状 AA 的疗效与传统的局部注射相当，且疼痛减轻。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of the American Academy of Dermatology 医学-皮肤病学

CiteScore

8.60

自引率

5.80%

发文量

2023

审稿时长

49 days

期刊介绍： The Journal of the American Academy of Dermatology (JAAD) is the official scientific publication of the American Academy of Dermatology (AAD). Its primary goal is to cater to the educational requirements of the dermatology community. Being the top journal in the field, JAAD publishes original articles that have undergone peer review. These articles primarily focus on clinical, investigative, and population-based studies related to dermatology. Another key area of emphasis is research on healthcare delivery and quality of care. JAAD also highlights high-quality, cost-effective, and innovative treatments within the field. In addition to this, the journal covers new diagnostic techniques and various other topics relevant to the prevention, diagnosis, and treatment of skin, hair, and nail disorders.